With the Food and Drug Administration approving the first COVID-19 vaccine for emergency use last week and another approval expected this week, the focus around the vaccine will start to shift toward public health messaging and how to convince tens of millions of people around the country to accept the ... READ MORE >
life sciences
5 things to know this week in life sciences: Week of Dec. 7
COVID-19 vaccine news continues to dominate headlines as candidates from several companies move closer to obtaining emergency use authorization from the Food and Drug Administration. Also on the drug approval front, tech giant Palantir and the FDA entered into a $44 million deal for the agency to use the ... READ MORE >
CHART OF THE DAY: Vaccine doses for the global population
With the U.S. Food and Drug Administration set to review Pfizer and BioNTech’s COVID-19 vaccine this week for emergency use authorization and Moderna’s vaccine next week, we have passed the “if” phase of questions around the vaccine. Now, the focus turns to the “when and how” of distribution. The ... READ MORE >
Looking ahead: next steps for the economy after Pfizer’s promising vaccine news
Pfizer and German biotech firm BioNTech’s Monday announcement that their COVID-19 vaccine candidate has shown to be more than 90% effective in preliminary results from an ongoing trial is a much needed win in the fight against the pandemic. It carries significant economic implications regarding the ... READ MORE >
The search for a safe and effective coronavirus vaccine
Regardless of race, religion or socioeconomic status, one thing most, if not all, Americans can agree on is that we are tired of the pandemic and the economic, health and political fallout we have collectively experienced from it. And while there may be disagreement about the best way to approach the ... READ MORE >
More promise, more problems: Cyberattacks threaten life sciences companies researching COVID-19 vaccine
Picture this scenario: Researchers at a biotech company are working tirelessly on a potential coronavirus vaccine and planning to start a phase three clinical trial soon. This work results in more visibility for the company, and an influx of capital investment. But with that greater visibility and ... READ MORE >
Trump administration identifies 5 companies for government support in vaccine effort
Drug developers, academic institutions and government agencies across the globe are investigating more than 100 potential vaccines for the coronavirus. The Trump administration on Wednesday identified a handful of organizations that it believes are the most likely to produce a viable vaccine candidate, ... READ MORE >
Shadow IT risk is growing as health care industry consolidates
As U.S. health care systems continue to consolidate, they must be aware of the information technology risks lurking in the shadows. The pace of consolidation remained strong last year, with approximately 1,600 deals. And while megamergers are expected to slow in 2020, larger organizations continue ... READ MORE >
Biotech needs cash in hesitant market
Life science companies require a cash infusion at least twice as big as that of 2018 to fund research and development at a time when investors remain skittish, according to a Bloomberg analysis. The analysis suggests that over 100 biotech companies, including makers of oncology therapies and treatments ... READ MORE >